LPA and atherosclerosis: In a phase 2 trial, a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established ASCVD and screening Lp(a) levels of at least 60 mg/dL (150 nmol/L), pelacarsen effectively reduced Lp(a) levels in a dose-dependent way (i.e., 35% at the dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week) [73].